summit clinical trial tirzepatide An Observational Study of Cardiovascular Outcomes of vs Glucagon-Like Peptide-1 Receptor Agonists SUMMIT: Benefits From Tirzepatide Similar

The fight in South Africa offers an early picture of what could happen in other emerging markets as key patents expire

Tirzepatide, a dual glucagon-like peptide-1 (GIP) and GLP-1RAs, administered once weekly at a 15 mg dose, resulted in an average weight loss of 20.9% over 72 weeks (Jastreboff et al., 2022), driven by its synergistic effects on appetite regulation, energy intake reduction, and fat mass decrease (Heise et al., 2023)

Available Strengths Levothyroxine and Synthroid are available in the following strengths: 25 mcg 50 mcg 75 mcg 88 mcg 100 mcg 112 mcg 125 mcg 137 mcg 150 mcg 175 mcg 200 mcg 300 mcg Side Effects Side effects of levothyroxine may resemble symptoms of hyperthyroidism: Irregular heartbeat Chest pain or shortness of breath Muscle weakness Headache, irritability, or insomnia Hives or rash Tremors Appetite changes or weight loss Diarrhea or vomiting Sensitivity to heat, sweating, or fever Changes in menstrual cycles Hair loss (usually temporary) Serious Side Effects Heart failure symptoms: fatigue, swelling, shortness of breath Heart attack symptoms: chest pain, dizziness, cold sweats Severe allergic reactions: hives, facial swelling, breathing issues Note: This is not a complete list

SAM-e has been approved and marketed as a treatment for psychiatric disorders in Europe for over 25 years, but, in the US, it is sold as an over-the-counter supplement [ R ]